MAP3K8 and non-small cell lung carcinoma: This approval was later extended to detect the T790M acquired resistance mutation of the EGFR in phase II studies of osimertinib in EGFR-mutant NSCLC with acquired resistance to kinase inhibitors (AURA extension; NCT0180-2632 and AURA2; NCT02094261) using plasma and tissue pairs collected from patients with EGFR-mutant NSCLC.